Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.
about
Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers.Multifunctional, stimuli-sensitive nanoparticulate systems for drug deliveryEnhancing siRNA-based cancer therapy using a new pH-responsive activatable cell-penetrating peptide-modified liposomal system.Barriers to drug delivery in solid tumors.Natural product modulators to overcome multidrug resistance in cancer.Modifications of natural peptides for nanoparticle and drug design.Review peptide-targeted liposomes for selective drug delivery: Advantages and problematic issues.Intracellular delivery of nanocarriers and targeting to subcellular organelles.Recent in vivo advances in cell-penetrating peptide-assisted drug delivery.The achievement of ligand-functionalized organic/polymeric nanoparticles for treating multidrug resistant cancer.Efficient in vivo gene delivery using modified Tat peptide with cationic lipids.Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.Nanotechnology and Glycosaminoglycans: Paving the Way Forward for Ovarian Cancer Intervention.
P2860
Q35772168-3A9FB915-05BA-40BE-BCEB-53D8A9A6E739Q35809872-6C5DD0AF-6A1E-46E5-BDA3-C22722837A2FQ37735811-7BE26E3C-F173-4972-BD7D-5C016F7726AAQ38234567-7E15D46F-142F-41A5-9DC2-C40066984CB7Q38343461-73F853C0-4EEA-4D13-8634-F6FD48716634Q38369494-47051C12-0D0F-4FE8-B079-5B8EABE6866FQ38502588-2BD73011-A6A0-43F5-B680-F6E80AC2188FQ38584491-2351CBD3-B9C6-48E6-9E83-EE8458D8F7A7Q38658534-C7421566-043B-4731-8C2B-D0CFAF5AEBB4Q38809044-6BC24D8D-1375-4165-999B-7041FBAC255CQ42235051-E396CFBB-2824-4557-A3F9-C6CE4C415AC3Q50058387-95A47EC0-48CB-4990-83A1-1743DB2B3827Q55018323-A8CCCBB7-907B-4004-BD71-77F7E15BF634
P2860
Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Doxorubicin in TAT peptide-mod ...... sistant ovarian cancer models.
@en
Doxorubicin in TAT peptide-mod ...... sistant ovarian cancer models.
@nl
type
label
Doxorubicin in TAT peptide-mod ...... sistant ovarian cancer models.
@en
Doxorubicin in TAT peptide-mod ...... sistant ovarian cancer models.
@nl
prefLabel
Doxorubicin in TAT peptide-mod ...... sistant ovarian cancer models.
@en
Doxorubicin in TAT peptide-mod ...... sistant ovarian cancer models.
@nl
P2093
P2860
P356
P1476
Doxorubicin in TAT peptide-mod ...... sistant ovarian cancer models.
@en
P2093
Alexander Koshkaryev
Anjali Apte
Erez Koren
Vladimir P Torchilin
P2860
P356
10.4161/CBT.26609
P577
2013-10-21T00:00:00Z